Raytheon Company wins $37 million contract supporting Evolved Sea Sparrow Missile
Get Alerts RTN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., Jan. 14, 2019 /PRNewswire/ -- Raytheon Company (NYSE: RTN) was awarded the following contract as announced by the Department of Defense on December 21, 2018.

Raytheon Co., Tuscon, Arizona, is being awarded a $37,902,562 cost-plus-fixed-fee modification to previously-awarded contract N00024-16-C-5433 to exercise options in support of Evolved Sea Sparrow Missile (ESSM) design agent, in-service support and technical engineering support services. Fiscal 2019 other country; fiscal 2018 weapons procurement (Navy); fiscal 2019 research, development, test and evaluation (Navy); Foreign Military Sales; and fiscal 2019 operations and maintenance funding in the amount of $16,663,004 will be obligated at time of award, and funds in the amount of $208,225 will expire at the end of the current fiscal year. This is a sole-source contract pursuant to an international agreement between the U.S. and nine other countries. The Naval Sea Systems Command, Washington, District of Columbia, is the contracting activity.
About RaytheonRaytheon Company, with 2017 sales of $25 billion and 64,000 employees, is a technology and innovation leader specializing in defense, civil government and cybersecurity solutions. With a history of innovation spanning 96 years, Raytheon provides state-of-the-art electronics, mission systems integration, C5I™ products and services, sensing, effects, and mission support for customers in more than 80 countries. Raytheon is headquartered in Waltham, Massachusetts. Follow us on Twitter.
Media ContactMike Doble+1.703.284.4345[email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/raytheon-company-wins-37-million-contract-supporting-evolved-sea-sparrow-missile-300777967.html
SOURCE Raytheon Company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Digital Marketing Agency Launches for Health and Wellness Brands
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- Athena Gold Announces Virtual 2026 Annual General and Special Meeting to be Held July 24, 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share